ŞBŞeyma Benli

Şeyma Benli

*This is an algorithmically generated author record based on publicly available information.

Şeyma Benli has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Peripheral inflammatory markers and metabolic profiles in temporal lobe epilepsy and functional dissociative seizures

    by Betül Merd, Şeyma Benli, Fatmanur Merd, İnAyet Güntürk, Cevat Yazici, Meltem Sönmez, Füsun Ferda Erdoğan

    Background: Temporal lobe epilepsy (TLE) and functional dissociative seizures (FDS) are distinct conditions that share overlapping clinical, neuropsychiatric, and biological features, including depressive symptoms, obesity‐related metabolic dysregulation, and alterations in systemic inflammatory markers. Understanding the interplay among these factors may provide insight into their shared biological burden. Objective: This study aimed to investigate the relationships among systemic inflammatory markers, adipokines, obesity, seizure frequency, and depressive symptom burden in patients with drug‐resistant TLE, drug‐responsive TLE, and FDS. Methods: Seventy‐four patients were enrolled and divided into three groups: drug‐resistant TLE ( n = 24), drug‐responsive TLE ( n = 25), and FDS ( n = 25). Demographic and clinical data, physical activity levels, and depression scores were collected. Serum levels of IL‐1β, IL‐6, TNF‐α, BDNF, leptin, and adiponectin were measured using ELISA. Group comparisons were initially performed using One‐Way ANOVA or Kruskal‐Wallis tests. Multiple linear regression models were subsequently constructed to adjust for potential confounders, including age, sex, and body mass index (BMI). Adjusted p values < 0.05 were considered statistically significant. Results: In crude analyses, IL‐1β, leptin, and adiponectin levels differed significantly across groups. However, after adjustment for age, sex, and BMI, only leptin (adjusted p = 0.014) and adiponectin (adjusted p = 0.005) remained significantly associated with the diagnostic group. The difference in IL‐1β levels did not retain statistical significance after adjustment (adjusted p = 0.067). IL‐6, TNF‐α, and BDNF levels did not differ significantly between groups in either crude or adjusted analyses. Beck Depression Inventory scores were numerically higher in the FDS and drug‐resistant TLE groups, but the difference did not reach statistical significance. No significant differences were observed in BMI or physical activity levels, and the majority of participants were classified as overweight or having stage 1 obesity. Conclusion: After controlling for age, sex, and BMI, metabolic markers—particularly leptin and adiponectin—remained independently associated with diagnostic group, whereas inflammatory cytokines did not demonstrate robust independent differences. These findings suggest that metabolic dysregulation may represent a more prominent differentiating factor than systemic inflammation among patients with TLE and FDS.

  • Evaluation of serum irisin and meteorin‐like ( METRNL ) levels in people with drug‐resistant and drug‐responsive temporal lobe epilepsy

    by Esranur Kaya, Şeyma Benli, Didem Barlak Keti, Can Koğ, Ravza Tosunbayraktar, Füsun Ferda Erdoğan

    Objective: Temporal lobe epilepsy (TLE) is associated with significant comorbidities, including cognitive decline and psychiatric disorders. Myokines, such as irisin and meteorin‐like (METRNL) hormone, are secreted during physical activity and possess neuroprotective and anti‐inflammatory properties. This study aimed to evaluate serum irisin and METRNL concentrations in people with TLE (drug‐resistant and drug‐responsive) compared to healthy controls and to analyze their correlation with depression, anxiety, cognitive function, and physical activity. Materials and Methods: This cross‐sectional study included adult participants divided into three groups: drug‐resistant TLE, drug‐responsive TLE, and healthy controls. Serum irisin and METRNL levels were quantified using ELISA. Neuropsychological status was assessed using the Beck Depression Inventory (BDI), Spielberger State–Trait Anxiety Inventory (STAI), and Mini‐Mental State Examination (MMSE). Physical activity was evaluated using the International Physical Activity Questionnaire (IPAQ). Results: Serum METRNL levels were significantly lower in both the drug‐resistant and drug‐responsive TLE groups compared to the control group ( p = .001). Multivariable regression analysis confirmed that epilepsy status was independently associated with lower METRNL levels ( p = .039). Conversely, serum irisin levels did not differ significantly among the groups ( p = .124). Participants with TLE exhibited significantly lower physical activity and MMSE scores compared to controls. Additionally, the drug‐resistant TLE group showed significantly higher depression and state anxiety scores. A positive correlation was observed between physical activity levels and serum METRNL concentrations. Conclusion: Serum METRNL levels are significantly reduced in people with TLE regardless of drug resistance, whereas irisin levels remain unchanged. The reduction in METRNL may reflect underlying neuroinflammatory or metabolic dysfunctions associated with epilepsy. Given the association between physical activity and METRNL, lifestyle interventions may offer therapeutic potential. METRNL warrants further investigation as a candidate biomarker for TLE.


  • Nöromyelitis Optika ve Tedavisi

    by Şeyma Benli

    Nöromyelitis optika spektrum bozukluğu (NMOSD), optik sinirleri ve spinal kordu öncelikli olarak etkileyen, merkezi sinir sisteminin nadir ve antikor aracılı otoimmün bir hastalığıdır. Bu bölüm, hastalığın tarihsel gelişiminden başlayarak epidemiyolojisini, akuaporin-4 (AQP4) antikorlarının rolüne odaklanan immünopatogenezini ve klinik sunumlarını detaylandırmaktadır. Özellikle 2015 Uluslararası Konsensüs Tanı Kriterleri ışığında AQP4-IgG pozitif ve negatif olguların yönetimi, karakteristik görüntüleme bulguları ve Multipl Skleroz (MS) ile olan ayırıcı tanısı üzerinde durulmuştur. Bölümün odak noktası güncel tedavi stratejileridir. Akut atak yönetiminde kullanılan yüksek doz kortikosteroidler ve plazma değişiminin (plazmaferez) yanı sıra, uzun vadeli atak önleyici tedaviler kapsamlıca incelenmiştir. Klasik immünosüpresanlardan (azatioprin, mikofenolat mofetil), hastalığın seyrini değiştiren ve son yıllarda onay alan yeni nesil monoklonal antikorlara (rituksimab, ekulizumab, inebilizumab, satralizumab ve ravulizumab) kadar geniş bir yelpazedeki tedavi seçeneklerinin etkinlikleri, güvenlik profilleri ve etki mekanizmaları güncel literatür verileri eşliğinde sunulmaktadır.

  • Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Long-term Follow-up and Therapeutic Challenges in a Treatment-Resistant Case

    by Mehmet Fatih Yetkin, Şeyma Benli, Meral Mirza

    Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition primarily affecting the optic nerve and spinal cord, often resulting in significant disability. This case study follows a 40-year-old female patient with pediatric-onset neuromyelitis optica spectrum disorder, initially misdiagnosed with multiple sclerosis, which led to inappropriate treatment and exacerbated her condition. Over the years, the patient received multiple immunosuppressive therapies—including azathioprine, rituximab, and tocilizumab—with limited clinical efficacy. The introduction of eculizumab, combined with azathioprine, eventually improved her disease control, albeit with some relapses. This case highlights the challenges in managing treatment-resistant neuromyelitis optica spectrum disorder and underscores the importance of accurate diagnosis and tailored therapies to improve long-term outcomes for patients. Ongoing research and personalized treatment strategies are crucial for effectively managing refractory cases.


  • Open Access

    COVID-19 Hastalarında İnme Sıklığının Değerlendirilmesi

    by Recep Baydemi̇r, Hümeyra Aslaner, Gamze Kalin Ünüvar, Murat Gülteki̇n, Şeyma Benli̇, Ali Ramazan Benli̇

    Objective: Neurological symptoms occur due to central and peripheral nervous system involvement with different mechanisms in coronavirus disease 2019 (COVID-19). Microvascular thrombosis develops with prothrombotic activation along with the increase in cytokines in COVID-19 infection. We aimed to investigate the incidence of cerebrovascular disease and concomitant risk factors in COVID-19 positive patients.Materials and Methods: Acute and temporally related cerebrovascular diseases with a diagnosis of COVID-19 were evaluated. Cerebrovascular events were assessed in 4 groups as ischemic and hemorrhagic events, transient ischemic attacks, and cerebral venous thrombosis. Risk factors for cerebrovascular disease in these patients were also assessed, and which risk factors for cerebrovascular diseases in COVID-19 patients are high risk were examined.Results: Of the 1000 patients with COVID-19 disease were evaluated. Ischemic cerebrovascular disease and/or transient ischemic attack were found in 14 patients (1.4%). The most common symptoms related to COVID-19 were fever and respiratory distress in 14 patients with acute ischemic stroke diagnosed with COVID-19.Conclusion: COVID-19 increases the risk of stroke in patients with multiple risk factors. Close follow-up should be performed more carefully, especially in patients with pulmonary involvement and acute ischemic stroke, because mortality is likely to be higher.